Education
About Us
Working with TipRanks
Follow Us
Agenus Inc. (AGEN)
:AGEN
AGEN Stock Chart & Stats
$4.34
-$0.06(-1.69%)
At close: 4:00 PM EST
$4.34
-$0.06(-1.69%)
Day’s Range― - ―
52-Week Range$1.38 - $7.34
Previous CloseN/A
Volume199.21K
Average Volume (3M)483.50K
Market Cap
$142.84M
Enterprise Value$457.26M
Total Cash (Recent Filing)$3.46M
Total Debt (Recent Filing)$45.77M
Price to Earnings (P/E)―
Beta3.29
Next Earnings
Mar 12, 2026EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.94
Shares Outstanding34,008,350
10 Day Avg. Volume544,068
30 Day Avg. Volume483,504
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.18
Price to Sales (P/S)0.57
P/FCF Ratio-0.37
Enterprise Value/Market Cap3.20
Enterprise Value/Revenue4.28
Enterprise Value/Gross Profit5.32K
Enterprise Value/Ebitda13.72
Forecast
1Y Price Target
$23.00Price Target Upside429.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company plans to expand the clinical evidence supporting bot/bal in metastatic MSS-CRC along with the BATTMAN trial and in earlier lines including the neoadjuvant setting for MSS-CRC and other tumor types via partnerships and ISTs.
Financial TransactionsAgenus has agreed to sell its California-based CMC manufacturing facilities to Zydus, providing an essential $91M injection of capital to administer the BATTMAN Phase 3 trial.
Regulatory ApprovalsFrance's medicine agency authorized compassionate access for bot/bal in patients with metastatic MSS-CRC without LMs, signaling early positive regulatory sentiment toward bot/bal's safety and efficacy.
Bears Say
Agenus News
AGEN FAQ
What was Agenus Inc.’s price range in the past 12 months?
Agenus Inc. lowest stock price was $1.38 and its highest was $7.34 in the past 12 months.
What is Agenus Inc.’s market cap?
Agenus Inc.’s market cap is $142.84M.
When is Agenus Inc.’s upcoming earnings report date?
Agenus Inc.’s upcoming earnings report date is Mar 12, 2026 which is in 102 days.
How were Agenus Inc.’s earnings last quarter?
Agenus Inc. released its earnings results on Nov 10, 2025. The company reported $1.94 earnings per share for the quarter, missing the consensus estimate of $2.197 by -$0.257.
Is Agenus Inc. overvalued?
According to Wall Street analysts Agenus Inc.’s price is currently Undervalued.
Does Agenus Inc. pay dividends?
Agenus Inc. does not currently pay dividends.
What is Agenus Inc.’s EPS estimate?
Agenus Inc.’s EPS estimate is 0.47.
How many shares outstanding does Agenus Inc. have?
Agenus Inc. has 34,008,350 shares outstanding.
What happened to Agenus Inc.’s price movement after its last earnings report?
Agenus Inc. reported an EPS of $1.94 in its last earnings report, missing expectations of $2.197. Following the earnings report the stock price went up 5.779%.
Which hedge fund is a major shareholder of Agenus Inc.?
Currently, no hedge funds are holding shares in AGEN
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (429.95% Upside)
$23.00 (429.95% Upside)
Blogger Sentiment
Neutral
AGEN Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 127.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.93%
Trailing 12-Months
Company Description
Agenus Inc.
Agenus (AGEN) is a biotechnology company focused on the discovery and development of immuno-oncology therapies to treat cancer. The company operates primarily in the biopharmaceutical sector, leveraging its proprietary technology platforms to create a diverse pipeline of product candidates, which includes immune checkpoint modulators, cancer vaccines, and other immunotherapeutics. Agenus aims to harness the body's immune system to fight cancer, with a commitment to advancing novel therapies that can improve patient outcomes.
AGEN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several positive developments, including strategic hires, promising BOT/BAL data, and multiple capital proposals which could strengthen the company's financial position. However, financial metrics such as a decreased cash balance and lower revenue compared to the previous year, alongside ongoing regulatory challenges, present notable challenges. The overall sentiment is cautiously optimistic as the highlights and lowlights are balanced.View all AGEN earnings summariesAGEN Stock 12 Month Forecast
Average Price Target
$23.00
▲(429.95% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
Oncolytics Biotech
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Ownership Overview
2.14% Insiders
11.70% Mutual Funds
5.03% Other Institutional Investors
76.84% Public Companies and
Individual Investors